Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Rigel Pharmaceuticals (NASDAQ:RIGL). Now ...
Investors might want to bet on Rigel Pharmaceuticals (RIGL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Rigel Pharmaceuticals (NASDAQ:RIGL) delivered much higher GAAP revenue and profits than analysts expected for Q2 2025, boosted by both strong product sales and non-cash collaboration revenue. Net ...
Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...
Rigel achieved its first full-year net income of $17.5 million. Q4 2024 net product sales grew by 58% year-over-year to $46.5 million. The company anticipates 30% year-over-year net product sales ...
Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based ...
Rigel Pharmaceuticals shows growth in Q2 2023 earnings with increased revenues and reduced net loss, but concerns remain over financial stability. The company focuses on expanding hematology/oncology ...
SOUTH SAN FRANCISCO, Calif., June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback